Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cevec Announces that CAP Cells Produce High Titers of RSV Vaccine

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Company announces excellent data from an evaluation program for RSV vaccine production.

CEVEC Pharmaceuticals has announced excellent data from an evaluation program for production of RSV vaccine in CAP cells. The data were obtained in a collaborative project with Paragon Bioservices Inc., a leading US biopharmaceutical contract manufacturer (CMO), and show that CAP cells were able to produce very high titers of RSV.

Moreover and in contrast to other production systems, RSV produced in CAP cells show high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.

With these data CAP cells prove again that they are an excellent tool as an expression system for different vaccines, meeting the highest regulatory demands and process requirements.

Even though many common diseases of childhood can now be prevented by early vaccination, currently there is still no vaccine approved to prevent RSV infection.

Worldwide it is estimated that RSV is responsible for a very high number of hospitalized infants and nearly seven percent of deaths in babies in their first year of life.

“Again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines,” commented Dr. Rainer Lichtenberger, COO / CFO of CEVEC.

Dr. Lichtenberger continued, “Next to Cytomegalovirus, Influenza and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful.”

“The data obtained here will further help to position our CAP technology as unique production system also in the vaccine market”, added Wolfgang Kintzel, CEO of CEVEC. “CAP cells have already proven their immense potential for the production of therapeutic proteins in preclinical settings and in clinical trials. They are currently the only independent human cell line available for the production of such a broad array of biopharmaceuticals including both, vaccines and proteins.”

Paragon’s CEO Marco Chacón agrees, “This teamwork pays not only for CEVEC, but also for Paragon. With use of CAP cells we can offer our customers a unique production system to meet the challenges of their vaccine target. With this highly ambitious project we have again proven our expertise in this competitive business.”

CAP cells are an immortalized cell line derived from primary human amniocytes that meet the highest ethical and regulatory standards.

CAP cells grow in serum-free suspension culture and allow for stable production of proteins and viruses / vaccines.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!